Drug intelligence / Profile preview

RLVT-9-01

Development stage: Preclinical
Lead developer: Releviate Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**RLVT-9-01** is a human monoclonal antibody developed by Releviate Therapeutics under exclusive license from the University of California, Riverside and Duke University. It specifically targets and inhibits **matrix metalloproteinase 9 (MMP-9)**, a key enzyme implicated as a molecular switch that activates acute neuropathic pain pathways. The drug is in preclinical development for chronic pain indications, particularly neuropathic pain, with potential applications in conditions involving MMP-9 dysregulation.[5][6][7]

Targets

MMP9 (Matrix metalloproteinase-9)

Beyond the preview

Go deeper on RLVT-9-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RLVT-9-01.

Explore the full profile